Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T2 Protect AD: Troriluzole in Mild to Moderate Alzheimer's Disease
NCT03605667Phase 2Completed
- Sponsor
- Biohaven Ltd.
- Start
- Jul 2018
- Primary completion
- Dec 2020
- Modality
- Allosteric Modulators, Orthosteric Ligands, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of troriluzole in Alzheimer's disease (AD), sponsored by Biohaven Ltd.. Started Jul 2018; status: completed.
02
Drugs
troriluzole
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03605667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03605667.